Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects

• Main Authors: Shan Jing (Author), Yang Lin (Author), Randy Dockens (Author), David Marchisin (Author), Bing He (Author), Ihab G. Girgis (Author), Anjaneya Chimalakonda (Author), Bindu Murthy (Author), Urvi Aras (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2023-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, blocks cytokine signaling involved in psoriasis pathogenesis. This ethnic-bridging study evaluated deucravacitinib pharmacokinetics, tolerability, and safety in healthy Chinese subjects. Methods This p...